The company expects that this work to develop and validate classifier models for bladder cancer will lead to a CE mark for its Qlucore Diagnostics software platform.
Following on a monotherapy study initiated last year, the new study will combine two of Day One's investigational compounds: a Raf kinase inhibitor and a MEK inhibitor.
The company plans to seek accelerated approval for the regimen after seeing a 38 percent objective response rate in the MOUNTAINEER trial.
The trial at Barts Cancer Institute will follow 200 prostate cancer patients over five years and gauge if the CTC test can identify who will recur after surgery.
Bayer has notified Atara of plans to terminate its exclusive worldwide licensing deal for the mesothelin-directed cell therapies ATA3271 and ATA2271.
Tests like MDxHealth's SelectMDx, Bio-Techne's ExoDx Prostate, and various PSA scoring algorithms would be reimbursed if they pass a technical assessment.
The trial will explore whether ALRN-6924 prevents toxicity in patients receiving neoadjuvant chemotherapy treatment.
The company will use the funds to advance development of its CAR-T, CAR-M, and CAR-NK programs into the clinic.
The partners will see if the oncolytic virus CF33-hNIS, dubbed Vaxinia, can increase PD-L1 tumor expression and make patients responsive to Merck's Keytruda.